Serum: differential pricing of the Covid-19 vaccine
Sunny Vijay Arora, Malay Krishna
Informasi Umum
Kode
24.10.268
Klasifikasi
658.816 - Pricing
Jenis
Case Studies
Subjek
Pricing
No. Rak
Dilihat
177 kali
Informasi Lainnya
Abstraksi
This case outlines the decisions that Adar Poonawalla, the CEO of Serum Institute of India (Serum), had to make in late April 2021 concerning its pricing for the COVID-19 (Covid) vaccine. Serum was the world’s largest manufacturer of vaccines, and its Covishield vaccine had received regulatory approval, but faced an unusual challenge and opportunity. In most countries, governments had procured Covid vaccines from manufacturers and then delivered the vaccines to consumers free of cost. But in India, there was a three-tier pricing system. While the Government of India had committed to free vaccines in government-run public hospitals, it also allowed vaccine makers to directly sell vaccines to state governments, as well as private hospitals, who were at liberty to charge consumers for the vaccines. This created an interesting pricing dilemma for Serum: as different customers had different willingness to pay, should Serum use differential pricing? Would such a tiered pricing system be considered fair? How many different price points should Serum maintain? By exploring these and related decisions that Poonawalla had to make, the case is intended to teach price discrimination.
Koleksi & Sirkulasi
Tersedia 1 dari total 1 Koleksi
Anda harus log in untuk mengakses flippingbook
Pengarang
| Nama | Sunny Vijay Arora, Malay Krishna |
| Jenis | Perorangan |
| Penyunting | |
| Penerjemah |
Penerbit
| Nama | Emerald |
| Kota | New York |
| Tahun | 2024 |
Sirkulasi
| Harga sewa | IDR 0,00 |
| Denda harian | IDR 0,00 |
| Jenis | Non-Sirkulasi |
